BG108253A - ДИХИДРО-БЕНЗО[b][1,4] ДИАЗЕПИН-2-ОН ПРОИЗВОДНИ КАТО mGluR2 АНТАГОНИСТИ I - Google Patents

ДИХИДРО-БЕНЗО[b][1,4] ДИАЗЕПИН-2-ОН ПРОИЗВОДНИ КАТО mGluR2 АНТАГОНИСТИ I Download PDF

Info

Publication number
BG108253A
BG108253A BG108253A BG10825303A BG108253A BG 108253 A BG108253 A BG 108253A BG 108253 A BG108253 A BG 108253A BG 10825303 A BG10825303 A BG 10825303A BG 108253 A BG108253 A BG 108253A
Authority
BG
Bulgaria
Prior art keywords
phenyl
diazepin
trifluoromethyl
oxo
dihydro
Prior art date
Application number
BG108253A
Other languages
Bulgarian (bg)
English (en)
Inventor
Geo Adam
Erwin Goetschi
Vincent Mutel
Juergen Wichmann
Johannes Woltering
Original Assignee
F.Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann - La Roche Ag filed Critical F.Hoffmann - La Roche Ag
Publication of BG108253A publication Critical patent/BG108253A/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG108253A 2001-04-12 2003-10-10 ДИХИДРО-БЕНЗО[b][1,4] ДИАЗЕПИН-2-ОН ПРОИЗВОДНИ КАТО mGluR2 АНТАГОНИСТИ I BG108253A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01109126 2001-04-12

Publications (1)

Publication Number Publication Date
BG108253A true BG108253A (bg) 2005-03-31

Family

ID=8177127

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108253A BG108253A (bg) 2001-04-12 2003-10-10 ДИХИДРО-БЕНЗО[b][1,4] ДИАЗЕПИН-2-ОН ПРОИЗВОДНИ КАТО mGluR2 АНТАГОНИСТИ I

Country Status (37)

Country Link
US (1) US6548495B2 (de)
EP (1) EP1379522B1 (de)
JP (1) JP4043953B2 (de)
KR (1) KR100566178B1 (de)
CN (1) CN1268626C (de)
AR (1) AR035456A1 (de)
AT (1) ATE287883T1 (de)
AU (1) AU2002310912B2 (de)
BG (1) BG108253A (de)
BR (1) BR0208887A (de)
CA (1) CA2441771C (de)
CZ (1) CZ20033002A3 (de)
DE (1) DE60202761T2 (de)
DK (1) DK1379522T3 (de)
EC (1) ECSP034796A (de)
ES (1) ES2235044T3 (de)
GT (1) GT200200072A (de)
HR (1) HRP20030791B1 (de)
HU (1) HUP0400991A3 (de)
IL (2) IL158021A0 (de)
JO (1) JO2273B1 (de)
MA (1) MA27011A1 (de)
MX (1) MXPA03009317A (de)
MY (1) MY130369A (de)
NO (1) NO325300B1 (de)
NZ (1) NZ528345A (de)
PA (1) PA8543201A1 (de)
PE (1) PE20021072A1 (de)
PL (1) PL367086A1 (de)
PT (1) PT1379522E (de)
RU (1) RU2270197C2 (de)
SI (1) SI1379522T1 (de)
SK (1) SK13692003A3 (de)
UY (1) UY27259A1 (de)
WO (1) WO2002083665A1 (de)
YU (1) YU79103A (de)
ZA (1) ZA200307242B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02003740A (es) * 1999-10-15 2002-09-30 Hoffmann La Roche Derivados de benzodiazepina.
KR100764330B1 (ko) * 2003-07-25 2007-10-05 에프. 호프만-라 로슈 아게 급성 및/또는 만성 신경학적 장애의 치료를 위한mGluR2 길항제 및 AChE 억제제의 조합물
CA2586931C (en) 2004-11-05 2013-08-06 Paul Spurr Process for preparation of isonicotinic acid derivatives
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
JP2010524879A (ja) * 2007-04-19 2010-07-22 エフ.ホフマン−ラ ロシュ アーゲー ジヒドロ−ベンゾ[b][1,4]ジアゼピン−2−オンスルホンアミド誘導体
CA2696948C (en) 2007-09-14 2013-04-30 Jose Maria Cid-Nunez 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
KR20100080597A (ko) * 2007-09-14 2010-07-09 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 1,3-이치환된-4-페닐-1h-피리딘-2-온
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 1,3-이치환된 4-(아릴-x-페닐)-1h-피리딘-2-온
EP2220083B1 (de) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]-pyridin-derivate und ihre verwendung als positive allosterische modulatoren von mglur2-rezeptoren
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
BRPI0921333A2 (pt) 2008-11-28 2015-12-29 Addex Pharmaceuticals Sa derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EA020671B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2643320B1 (de) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridinderivate und ihre verwendung als positiv allosterische modulatoren des mglur2 receptors
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2602248A1 (de) 2011-12-05 2013-06-12 University Of Leicester Neue Pyrrol Verbindungen
KR20150070187A (ko) 2012-10-23 2015-06-24 에프. 호프만-라 로슈 아게 자폐 장애의 치료를 위한 mglu2/3 길항제
PL2963043T3 (pl) * 2013-02-28 2018-10-31 Eisai R&D Management Co., Ltd. Pochodna tetrahydroimidazo[1,5-d][1,4]oksazepiny
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
KR102414246B1 (ko) 2014-01-21 2022-06-27 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
EP3134089A2 (de) 2014-04-23 2017-03-01 F. Hoffmann-La Roche AG Mglu2/3-antagonisten zur behandlung von geistigen behinderungen
JP6552061B2 (ja) * 2014-06-10 2019-07-31 サンフォード−バーンハム メディカル リサーチ インスティテュート 代謝型グルタミン酸受容体の負のアロステリックモジュレーター(nams)とその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU953819A1 (ru) * 1980-08-25 1991-09-23 Физико-химический институт АН УССР 1-(Гидразинокарбонил)алкил-1,2-дигидро-3Н-1,4-бенздиазепин-2-оны, обладающие транквилизирующими и противосудорожными свойствами
EP1210338A2 (de) * 1999-08-05 2002-06-05 IGT Pharma Inc. 1,4-diazepin-derivate zur behandlung von krankheiten des zentralen nervensystems
TR200201023T2 (tr) * 1999-10-15 2002-09-23 F. Hoffmann-La Roche Ag Benzodiazepin türevleri.
MXPA02003740A (es) * 1999-10-15 2002-09-30 Hoffmann La Roche Derivados de benzodiazepina.

Also Published As

Publication number Publication date
US6548495B2 (en) 2003-04-15
YU79103A (sh) 2006-05-25
KR100566178B1 (ko) 2006-03-29
HUP0400991A3 (en) 2009-06-29
EP1379522B1 (de) 2005-01-26
CN1268626C (zh) 2006-08-09
CA2441771A1 (en) 2002-10-24
GT200200072A (es) 2003-06-19
NO20034496L (no) 2003-10-08
HK1068339A1 (en) 2005-04-29
IL158021A (en) 2010-04-15
ES2235044T3 (es) 2005-07-01
JO2273B1 (en) 2005-04-07
MA27011A1 (fr) 2004-12-20
BR0208887A (pt) 2004-06-29
SK13692003A3 (sk) 2004-05-04
HUP0400991A2 (hu) 2004-08-30
CN1522252A (zh) 2004-08-18
ATE287883T1 (de) 2005-02-15
PT1379522E (pt) 2005-05-31
SI1379522T1 (en) 2005-04-30
US20020198197A1 (en) 2002-12-26
HRP20030791B1 (en) 2006-06-30
PE20021072A1 (es) 2002-12-07
ZA200307242B (en) 2004-12-16
EP1379522A1 (de) 2004-01-14
ECSP034796A (es) 2003-12-01
DE60202761D1 (de) 2005-03-03
AU2002310912B2 (en) 2005-06-16
PA8543201A1 (es) 2002-10-31
JP4043953B2 (ja) 2008-02-06
DE60202761T2 (de) 2006-01-12
JP2004525965A (ja) 2004-08-26
DK1379522T3 (da) 2005-05-30
NO325300B1 (no) 2008-03-25
CA2441771C (en) 2008-12-30
PL367086A1 (en) 2005-02-21
MXPA03009317A (es) 2004-02-12
AR035456A1 (es) 2004-05-26
NZ528345A (en) 2005-04-29
RU2270197C2 (ru) 2006-02-20
UY27259A1 (es) 2002-10-31
NO20034496D0 (no) 2003-10-08
WO2002083665A1 (en) 2002-10-24
KR20030088502A (ko) 2003-11-19
IL158021A0 (en) 2004-03-28
MY130369A (en) 2007-06-29
RU2003130648A (ru) 2005-04-10
HRP20030791A2 (en) 2005-06-30
CZ20033002A3 (cs) 2004-03-17

Similar Documents

Publication Publication Date Title
EP1379522B1 (de) Dihydro-benzo(b)(1,4)diazepin-2-on-derivate als mglur2 antagonisten
EP1379511B1 (de) DIHYDRO-BENZO (b) (1,4) DIAZEPIN-2-ON-DERIVATE ALS MGLUR2 ANTAGONISTEN
AU2002310912A1 (en) Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mGluR2 antagonists I
ES2215738T3 (es) Derivados de benzodiazepina como receptor de glutamato metabotropico.
AU2002312788A1 (en) Dihydro-benzo [b] [1, 4] diazepin-2-one derivatives as mGluR2 antagonists II
CZ20021653A3 (cs) Nové deriváty benzodiazepinu
RU45093U1 (ru) Пылеуловитель